Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations
Status:
Not yet recruiting
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, two parallel group study assessing the efficacy and safety of neoadjuvant
and adjuvant targeted therapy in patients with stage IB-IIIA NSCLC harboring BRAF V600 or MET
exon14 mutations.